Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sm-TSP-2 + Alhydrogel + GLA-AF (National Institute of Allergy and Infectious Diseases)
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Sm-TSP-2 + Alhydrogel + GLA-AF is a recombinant protein subunit vaccine candidate developed for the prevention of intestinal and hepatic disease caused by the helminth parasite *Schistosoma mansoni*. The vaccine consists of the recombinant tetraspanin-2 (Sm-TSP-2) protein, which is a critical component of the parasite's outer tegument. It is formulated with Alhydrogel (aluminum hydroxide) and the Toll-like receptor 4 (TLR4) agonist GLA-AF (glucopyranosyl lipid A aqueous formulation) to enhance immunogenicity. By inducing antibodies against Sm-TSP-2, the vaccine aims to disrupt the integrity of the adult worm's tegument, thereby impairing its development and survival within the host. Development is supported by the National Institute of Allergy and Infectious Diseases (NIAID).
- Other names
- Sm-TSP-2/Alhydrogel/GLA-AFSm-TSP-2 vaccineSm-TSP2 vaccineSm-TSP 2 vaccine
02
Targets
Sm-TSP-2 (Schistosoma mansoni tetraspanin-2)TSPAN2 (Tetraspanin-2)
Beyond the preview
Go deeper on Sm-TSP-2 + Alhydrogel + GLA-AF (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sm-TSP-2 + Alhydrogel + GLA-AF (National Institute of Allergy and Infectious Diseases).